Activated myeloid cells produce increased levels of TNF-α, IL-6, IL-1β at the inflamed site, and this is reflected in the shared therapeutic approaches of blocking these cytokines in both RA and JIA (24–26). This evidence concerns the gene IL6 and rheumatoid arthritis.